CN109010260A - A kind of metronidazole vagina gel preparation - Google Patents
A kind of metronidazole vagina gel preparation Download PDFInfo
- Publication number
- CN109010260A CN109010260A CN201810822215.XA CN201810822215A CN109010260A CN 109010260 A CN109010260 A CN 109010260A CN 201810822215 A CN201810822215 A CN 201810822215A CN 109010260 A CN109010260 A CN 109010260A
- Authority
- CN
- China
- Prior art keywords
- metronidazole
- propylparaben
- methyl
- hydroxybenzoate
- gel preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of metronidazole vagina gel preparations, and the raw material for preparing the gel preparation includes: metronidazole, methyl p-hydroxybenzoate, propylparaben, propylene glycol, CARBOPOL 974P, natrium adetate and water；Wherein, the mass ratio of the methyl p-hydroxybenzoate and propylparaben is 2~6:1.Scheme provided by the invention shares metronidazole, methyl p-hydroxybenzoate, propylparaben and propylene glycol, methyl p-hydroxybenzoate and propylparaben are limited in specific proportional region, the common carbomer940 of the prior art is replaced with CARBOPOL 974P simultaneously, pharmaceutical effectiveness performance does not subtract after ensuring to replace auxiliary material, and and safety is higher.
Description
Technical field
The present invention relates to gynecopathy therapeutic and related drugs fields, and in particular to a kind of metronidazole vagina gel preparation.
Background technique
Bacterial vaginitis (BV) is a kind of mixed infection by vagina Gartner bacterium and some anaerobic bacterias, leads to intravaginal
Microecological balance imbalance, caused vaginal fluid increases, and leukorrhea has fish bad smell and the scorching hot syndrome of pruritus vulvue.It can divide
For haemophilus property vaginitis, Corynebacterium vaginitis, anaerobic bacteria vaginosis inflammation, Gardnerella Vaginalis Vaginitis etc..
The most frequently used drug of the metronidazole as bacterial vaginosis BV, clinical acceptance level are very high；" U.S.'s disease control in 2010
Vaginitis treatment guide in center processed " and " bacterial vaginosis BV diagnosis and treatment guide (draft) " preferred option for drafting of Chinese Medical Association it is equal
For metronidazole；But oral or ejection preparation side effect is big, is easy to produce anaphylactic shock and the nervous system disease, patient tolerability
Difference.The preparation that external application is made can then make drug mainly in the local action of medication, and pharmacokinetic study shows solidifying using vagina
Patient's metronidazole serum-concentration of glue preparation is only the 2% of oral preparation, Small side effects, and curative effect is better than oral preparation, Huan Zhenai
It is greatly improved by property.
However, existing metronidazole external preparation is easy to happen microbial contamination, and safety in storage and use process
It is not ideal enough.
Summary of the invention
It is an object of the invention to overcome the deficiencies of existing technologies, by metronidazole, methyl p-hydroxybenzoate, para hydroxybenzene
Propyl formate and propylene glycol share, and limit methyl p-hydroxybenzoate and propylparaben in specific proportional region
It is interior, while replacing the common carbomer940 of the prior art with CARBOPOL 974P, it is ensured that after replacement auxiliary material skin permeability and
Pharmaceutical effectiveness performance does not subtract, and safety is higher." P " in CARBOPOL 974P or carbomer940 of the present invention refers to that this is auxiliary
Material is orally available auxiliary material.
Specifically, preparing the raw material packet of the gel preparation the present invention provides a kind of metronidazole vagina gel preparation
Include: metronidazole, methyl p-hydroxybenzoate, propylparaben, propylene glycol, CARBOPOL 974P, natrium adetate and
Water；Wherein, the mass ratio of the methyl p-hydroxybenzoate and propylparaben be 2~6:1, preferably 3.5~
4.5:1。
The present invention by largely practice discovery, by metronidazole, methyl p-hydroxybenzoate, propylparaben and
Propylene glycol shares, and when the mass ratio of methyl hydroxybenzoate and propylparaben is in above-mentioned particular range, can be with
Ensure that gel has long-term stability.On the basis of the above, the present invention replaces the common card wave of the prior art with CARBOPOL 974P
Nurse 934P is easy output dissolvent residual, benzene toxicity is substantially since the technique that carbomer940 is benzene as the solvent used produces
Cancer, and 974p is produced with non-toluene solvent technique；Formula provided by the invention not only more meets pharmacopeia and relevant regulations
It is required that and pass through the synergistic effect with other components, it can be ensured that replacement auxiliary material after gel skin permeability and drug
Curative effect performance does not subtract, and safety is higher.
In order to reinforce the synergistic effect between each component, the further preferably described metronidazole of the present invention, P-hydroxybenzoic acid
The mass ratio of methyl esters and propylparaben is 35~40:2~6:1, more preferably 37~38:3.5~4.5:1.
To ensure Rational Dosage of the bacteriostatic agent in metronidazole vagina gel, guarantee finished product preparation inhibitory effect in validity period
It is not reduced because of holding conditions inside, the present invention is addition principle with minimum effective dose, is added to the reasonable of bacteriostatic agent in gelling agent
Dosage optimizes, and the content of specific preferably methyl p-hydroxybenzoate described in the gelling agent is 0.06~0.1%.As
Optimal case of the invention, the content of the methyl p-hydroxybenzoate are 0.07~0.09%, propylparaben
Content is 0.01~0.03%.The present invention is using stability test sample verifying preparation inhibitory effect it is found that working as the hydroxy benzenes
When methyl formate is in above-mentioned percentage range, products obtained therefrom does not reduce before the deadline because of holding conditions, has good
Stability.
As a preferred solution of the present invention, the raw material for preparing the gel preparation includes: 35~40 parts of metronidazole, right
2~6 parts of methyl hydroxybenzoate, 0.5~1.5 part of propylparaben, 130~160 parts of propylene glycol, CARBOPOL 974P
80~120 parts, 1~5 part of natrium adetate, 1~10 part of water.
As a kind of further preferred scheme of the invention, prepare the gel preparation raw material include: metronidazole 37~
38 parts, 3.5~4.5 parts of methyl p-hydroxybenzoate, 0.5~1.5 part of propylparaben, 140~150 parts of propylene glycol,
95~105 parts of CARBOPOL 974P, 2~3 parts of natrium adetate, 4~6 parts of water.
The pH value of the preferably described gel of the present invention is 4.0~4.5, to ensure that each component can cooperate under the pH environment
Good Antimicrobial preservative activity is played, especially ensures that gel has good skin permeability.
Present invention simultaneously provides a kind of methods for preparing the metronidazole vagina gel preparation.Specifically, the method
The following steps are included:
(1) natrium adetate is mixed with water, adds CARBOPOL 974P, sufficiently carry out vacuum emulsifying after swelling,
Obtain gel-type vehicle；
(2) pH value for adjusting the gel-type vehicle is 4.0~4.5, obtains Blank gel；
(3) methyl p-hydroxybenzoate and propylparaben are mixed with 2~6:1 of mass ratio and propylene glycol is added
In, obtain propylene glycol solution；The propylene glycol solution is mixed with water, be added metronidazole sufficiently dissolve, then with the Blank gel
Be sufficiently mixed to get.
The present invention optimizes the addition opportunity of each raw material and hybrid mode, it can be ensured that between each component more sufficiently
Ground mixing.Such as: step (1) is after being added CARBOPOL 974P, first sufficiently swelling, then carries out vacuum emulsifying, it can be ensured that
Each component more fully mixes, and products obtained therefrom has good skin permeability.
Sodium hydroxide is added in the present invention further preferably emulsification product obtained by the step (2), adjust pH value be 4.0~
4.5, obtain Blank gel.Present invention selection adjusts pH value when preparing Blank gel, it can be ensured that the mixing containing effective component
Solution and gel-type vehicle homogeneous keep optimal stable state when stirring, so that it is guaranteed that final product still has after placing for a long time
Good antibacterial effect and have good skin permeability.
Scheme provided by the invention is by metronidazole, methyl p-hydroxybenzoate, propylparaben and propylene glycol
It shares, limits methyl p-hydroxybenzoate and propylparaben in specific proportional region, while using carbomer
974P replaces the common carbomer940 of the prior art.Since the technique that carbomer 934 is benzene as the solvent used produces, hold
Easy output dissolvent residual, benzene toxicity is carcinogenic greatly, and 974p is produced with non-toluene solvent technique；Formula provided by the invention is not
Only more meet the requirement of pharmacopeia and relevant regulations, and pass through the synergistic effect with other components, it can be ensured that gel products exist
Skin permeability and pharmaceutical effectiveness performance after replacement auxiliary material do not subtract, and safety is higher.
Specific embodiment
The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention..
Embodiment 1
Present embodiments provide a kind of metronidazole vagina gel, raw material composition are as follows: metronidazole 600g, P-hydroxybenzoic acid
Methyl esters 64g, propylparaben 16g, propylene glycol 2.4kg, CARBOPOL 974P 1.6kg, natrium adetate 40g, water
75.28g；Sodium hydroxide adjusts pH value to 4.0；
The gelling agent is prepared by the following method:
(1) 58.5% dissolution natrium adetate of total amount of fetching water, CARBOPOL 974P is added in dispersion after dissolving completely, by material
It is added in vacuum homogeneous emulsifying machine, revolving speed controls 20r/min, stirs 4h, and temperature control is 40 DEG C during this, obtains gel base
Matter；
(2) sodium hydroxide is added in the gel-type vehicle, adjusting pH value is about 4.0, controls revolving speed 20r/min, stirring
30min obtains Blank gel；
(3) methyl p-hydroxybenzoate and propylparaben are added in propylene glycol, dissolve by heating to obtain propylene glycol
Solution；The 40% of total amount of fetching water, is heated to 50 DEG C, the propylene glycol solution is added, adds metronidazole, dissolve at 50 DEG C,
Obtain mixed solution；It after the mixed solution is cooled to 40 DEG C, is mixed with the Blank gel, vacuum homogeneous emulsifying machine is added
In, remaining water is added, stirs 2.5h, controls revolving speed 20r/min, temperature control is 40 DEG C during this, is obtained with finished product.
Embodiment 2
Present embodiments provide a kind of metronidazole vagina gel, raw material composition are as follows: metronidazole 592g, P-hydroxybenzoic acid
Methyl esters 56g, propylparaben 16g, propylene glycol 2.24kg, CARBOPOL 974P 1.52kg, natrium adetate 32g, water
64g；Sodium hydroxide adjusts pH value to 4.0.
The preparation method is the same as that of Example 1.
Embodiment 3
Present embodiments provide a kind of metronidazole vagina gel, raw material composition are as follows: metronidazole 608g, P-hydroxybenzoic acid
Methyl esters 72g, propylparaben 16g, propylene glycol 2.4kg, CARBOPOL 974P 1.68kg, natrium adetate 48g, water
96g；Sodium hydroxide adjusts pH value to 4.5.
The preparation method is the same as that of Example 1.
Embodiment 4
Present embodiments provide a kind of metronidazole vagina gel, raw material composition are as follows: metronidazole 560g, P-hydroxybenzoic acid
Methyl esters 32g, propylparaben 16g, propylene glycol 2.2kg, CARBOPOL 974P 1.28kg, natrium adetate 16g, water
16g；Sodium hydroxide adjusts pH value to 4.5.
The preparation method is the same as that of Example 1.
Embodiment 5
Present embodiments provide a kind of metronidazole vagina gel, raw material composition are as follows: metronidazole 640g, P-hydroxybenzoic acid
Methyl esters 96g, propylparaben 16g, propylene glycol 2.6kg, CARBOPOL 974P 1.92kg, natrium adetate 80g, water
160g；Sodium hydroxide adjusts pH value to 4.0.
The preparation method is the same as that of Example 1.
Embodiment 6
Present embodiments provide a kind of metronidazole vagina gel, raw material composition are as follows: metronidazole 1040g, para hydroxybenzene first
Sour methyl esters 64g, propylparaben 16g, propylene glycol 2.4kg, CARBOPOL 974P 1.6kg, natrium adetate 40g, water
75.28g；Sodium hydroxide adjusts pH value to 4.0.
The preparation method is the same as that of Example 1.
Experimental example
The resulting vaginal jellies of Example 1~6 and the metronidazole vagina gel original of listing grind sample (lot number GDDL with
And lot number KAAU), it is tested using artificial skin film according to following in vitro transdermal test method:
It (1) is 0.6cm by release area2Artificial skin film be fixed on Transdermal absorption instrument release pond one end, it is described artificial
The rough surface of skin membrane takes Metrogel test sample 0.15g to be spread evenly across the thick of the artificial skin film towards release pond
On matte；
(2) temperature for adjusting water in transdermal tester heat insulation trough is constant at 32 DEG C, and opens magnetic agitation；It is released described
It puts pond to be fixed on reception tank, 0.9% sodium chloride solution of 5ml is added in reception tank as receiving liquid, it is ensured that the artificial skin
The one side of the uncoated test sample of skin is contacted with the receiving liquid；It is fixed respectively at 0.5,1,2,3,4,5,6,7,8,9,10,12 hour
When sample 1ml, while the receiving liquid of equivalent equality of temperature is added；
(3) it after resulting reception sample filtering will be sampled, takes 50 μ l to inject high performance liquid chromatograph respectively, separately takes metronidazole
The solution of 6 μ g/ml is made for the transdermal measurement of artificial skin film, external standard method with receiving liquid dilution in appropriate reference substance
Metronidazole present in receiving liquid；Wherein, it uses octadecylsilane chemically bonded silica for filler, is the water-of 80:20 with volume ratio
Methanol is mobile phase, Detection wavelength 320nm；
(4) Percutaneous permeability Q:Qn=(A sample/A to the) × C for calculating drug according to following formula is right × and V+ ∑ qi to be to calculate
The accumulative transit dose of test sample.Wherein, Qn be different moments add up transit dose (μ g), A sample be receiving liquid peak area, A to for pair
According to the peak area of product solution, for C to the concentration (μ g/ml) for reference substance solution, V corresponds to the volume of receiving liquid, and qi is that i-th is real
The transit dose of survey；
With the time (h) for abscissa, transit dose (μ g) is ordinate, carries out linear fit, calculates whether metronidazole meets
Zero order kinetics release rule such as meets the transdermal rule of zero level, compares the slope from triturate and former triturate.
The instrument used in the present embodiment includes: high performance liquid chromatograph: Shimadzu LC-20AT；Transdermal absorption instrument: model
TT-6, Tianjin Zheng Tong Science and Technology Ltd.；Refiner: FSH-2, Jie Ruier Electrical Appliances Co., Ltd of Jintan City.
Wherein, the product data that embodiment 1 provides are as shown in table 1.
Table 1: drug accumulation transit dose measurement result table (n=6)
| Sample time | 0.5h | 1h | 2h | 3h | 4h | 5h | 6h | 8h | 9h | 10h | 12h |
| Min(μg) | 0.0 | 0.2 | 1.2 | 3.4 | 6.0 | 11.3 | 16.0 | 25.1 | 26.8 | 30.7 | 38.6 |
| Max(μg) | 0.8 | 1.1 | 3.5 | 7.4 | 13.9 | 20.3 | 30.3 | 50.5 | 53.9 | 61.3 | 75.7 |
| AV(μg) | 0.4 | 0.6 | 2.5 | 6.0 | 10.4 | 15.5 | 22.0 | 33.4 | 37.6 | 42.5 | 53.8 |
| RSD% | 87% | 54% | 33% | 25% | 27% | 20% | 22% | 27% | 25% | 26% | 26% |
Through detecting, with the time (h) for abscissa, transit dose (μ g) is ordinate, carries out linear fit, and each embodiment provides
Gel and commercially available original grind the R of product2Value is all larger than 0.98, meets the transdermal rule of zero level；Various embodiments of the present invention products obtained therefrom
Slope it is close with commercial product slope, illustrate that vaginal jellies transmitance provided by the invention is suitable with commercial product.It is above each
In embodiment, Examples 1 to 3 effect is preferable, and 1 effect of embodiment is best.
Although above having used general explanation, specific embodiment and test, the present invention is made to retouch in detail
It states, but on the basis of the present invention, it can be made some modifications or improvements, this is apparent to those skilled in the art
's.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to claimed
Range.
Claims (10)
1. a kind of metronidazole vagina gel preparation, which is characterized in that the raw material for preparing the gel preparation includes: metronidazole, right
Methyl hydroxybenzoate, propylparaben, propylene glycol, CARBOPOL 974P, natrium adetate and water；
Wherein, the mass ratio of the methyl p-hydroxybenzoate and propylparaben is 2~6:1.
2. metronidazole vagina gel preparation according to claim 1, which is characterized in that the methyl p-hydroxybenzoate with
The mass ratio of propylparaben is 3.5~4.5:1.
3. metronidazole vagina gel preparation according to claim 1, which is characterized in that the metronidazole, para hydroxybenzene first
The mass ratio of sour methyl esters and propylparaben is 35~40:2~6:1.
4. metronidazole vagina gel preparation according to claim 1, which is characterized in that the metronidazole, para hydroxybenzene first
The mass ratio of sour methyl esters and propylparaben is 37~38:3.5~4.5:1.
5. metronidazole vagina gel preparation described in any one according to claim 1~4, which is characterized in that the gelling agent
The content of middle methyl p-hydroxybenzoate is 0.06~0.1%.
6. metronidazole vagina gel preparation according to claim 1 or 5, which is characterized in that prepare the gel preparation
Raw material includes: 35~40 parts of metronidazole, and 2~6 parts of methyl p-hydroxybenzoate, 0.5~1.5 part of propylparaben, third
130~160 parts of glycol, 80~120 parts of CARBOPOL 974P, 1~5 part of natrium adetate, 1~10 part of water.
7. metronidazole vagina gel preparation according to claim 1 or 5, which is characterized in that prepare the gel preparation
Raw material includes: 37~38 parts of metronidazole, and 3.5~4.5 parts of methyl p-hydroxybenzoate, propylparaben 0.5~1.5
Part, 140~150 parts of propylene glycol, 95~105 parts of CARBOPOL 974P, 2~3 parts of natrium adetate, 4~6 parts of water.
8. metronidazole vagina gel preparation described in any one according to claim 1~7, which is characterized in that the metronidazole
The pH value of vaginal jellies preparation is 4~4.5.
9. the method for preparing metronidazole vagina gel preparation described in claim 1~8 any one, which is characterized in that including such as
Lower step:
(1) natrium adetate is mixed with water, adds CARBOPOL 974P, sufficiently carried out vacuum emulsifying after swelling, obtain solidifying
Gel matrix；
(2) pH value for adjusting the gel-type vehicle is 4.0~4.5, obtains Blank gel；
(3) methyl p-hydroxybenzoate and propylparaben are mixed with 2~6:1 of mass ratio and is added in propylene glycol, obtained
Propylene glycol solution；The propylene glycol solution is mixed with water, metronidazole is added and sufficiently dissolves, then is sufficiently mixed with the Blank gel
Close to get.
10. according to the method described in claim 9, it is characterized in that, it is 4.0 that sodium hydroxide is added in step (2) to adjust pH value
~4.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810822215.XA CN109010260A (en) | 2018-07-24 | 2018-07-24 | A kind of metronidazole vagina gel preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810822215.XA CN109010260A (en) | 2018-07-24 | 2018-07-24 | A kind of metronidazole vagina gel preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109010260A true CN109010260A (en) | 2018-12-18 |
Family
ID=64644808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810822215.XA Pending CN109010260A (en) | 2018-07-24 | 2018-07-24 | A kind of metronidazole vagina gel preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109010260A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO91013A2 (en) * | 1984-12-08 | 1987-02-27 | Intreprinderea De Produse Cosmetice"Nivea",Ro | VAGINAL GEL |
| CN102579322A (en) * | 2012-03-29 | 2012-07-18 | 河北科技大学 | Externally applied hydrogel agent and preparation method and application thereof |
| CN104546689A (en) * | 2015-01-07 | 2015-04-29 | 北京紫光制药有限公司 | Medicine composition containing metronidazole |
| WO2017117650A1 (en) * | 2016-01-10 | 2017-07-13 | Smilesonica Inc | Viscosity and stability modified ultrasound gel |
-
2018
- 2018-07-24 CN CN201810822215.XA patent/CN109010260A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO91013A2 (en) * | 1984-12-08 | 1987-02-27 | Intreprinderea De Produse Cosmetice"Nivea",Ro | VAGINAL GEL |
| CN102579322A (en) * | 2012-03-29 | 2012-07-18 | 河北科技大学 | Externally applied hydrogel agent and preparation method and application thereof |
| CN104546689A (en) * | 2015-01-07 | 2015-04-29 | 北京紫光制药有限公司 | Medicine composition containing metronidazole |
| WO2017117650A1 (en) * | 2016-01-10 | 2017-07-13 | Smilesonica Inc | Viscosity and stability modified ultrasound gel |
Non-Patent Citations (1)
| Title |
|---|
| 方亮: "《药用高分子材料学》", 31 August 2015, 北京：中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105213322A (en) | Pharmaceutical composition prepared by a kind of dry granulation process | |
| RU2015154681A (en) | GEL COMPOSITION FOR RADIATION THERAPY UNDER VISUAL CONTROL | |
| CN1146426C (en) | Stable aspirin-containing preparations for external use | |
| CN104013571A (en) | Ornidazole injection and preparing method thereof | |
| CN102784095A (en) | Glycyrrhetinic acid hydrogel preparation, its preparation method and its application | |
| Zhang et al. | Hydrogel‐based multifunctional dressing combining magnetothermally responsive drug delivery and stem cell therapy for enhanced wound healing | |
| CN102697755A (en) | Novel levo-carnitine hydrogel patch and preparation method thereof | |
| CN106727278B (en) | A kind of Timoptic-XE agent and preparation method thereof | |
| CN108853004A (en) | A method of preparing metronidazole vagina gel | |
| CN108721250B (en) | Biocompatible boric acid nano-drug compound and preparation method and application thereof | |
| CN109010260A (en) | A kind of metronidazole vagina gel preparation | |
| CN103735512A (en) | Enrofloxacin solid dispersion and preparation method thereof | |
| CN103417473B (en) | Adapalene gel and method for preparing same | |
| CN103494780B (en) | Gamithromycin composition lyophilized powder for injection and preparation method | |
| EP3984524A1 (en) | Ornidazole injection and s-ornidazole injection | |
| CN101612141A (en) | Buprenorphine patch | |
| CN113662912B (en) | Marbofloxacin controlled-release gel for livestock and preparation method thereof | |
| CN103830164A (en) | Moxifloxacin hydrochloride injection liquid and preparation method thereof | |
| CN106214636A (en) | A kind of diazepam injection pharmaceutical composition | |
| CN102697703A (en) | Piroxicam gel preparation and preparation method thereof | |
| CN105560166A (en) | Gynecological external antibacterial gel with silver ions and method for preparing gynecological external antibacterial gel | |
| JP6625208B2 (en) | Transdermal formulation | |
| CN105055379A (en) | External patch containing anastrozole and application thereof | |
| CN103989640A (en) | Ornidazole intravenous administration preparation and preparation method | |
| CN115400086B (en) | Policresulen liposome, preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181218 |
|
| RJ01 | Rejection of invention patent application after publication |